Rapid Versus Conventional Titration of Quetiapine in Schizophrenia/Schizoaffective Disorder (RAPID)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00457899
Recruitment Status : Terminated (Study terminated due to poor recruitment)
First Posted : April 9, 2007
Last Update Posted : November 27, 2007
Information provided by:

Brief Summary:
The purpose of this study is to determine whether increasing the amount (dose) of quetiapine IR (immediate release formulation) more rapidly than conventional dose increases, improves the control of symptoms as measured by the Positive and Negative Syndrome Scale (PANSS) - a psychiatric assessment scale that measures both positive and negative symptoms - in patients with acute schizophrenia or schizoaffective disorder.

Condition or disease Intervention/treatment Phase
Schizophrenia Schizoaffective Disorders Psychotic Disorders Drug: Quetiapine IR (Immediate Release) Phase 3

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 234 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: RAPID-An Open-Label Randomized, Multicenter Phase IIIb Study to Evaluate the Efficacy and Tolerability of Quetiapine IR (Immediate Release), Over 14 Days, in Acute Schizophrenia/Schizoaffective Disorder (Rapid Versus Conventional Titration)
Study Start Date : July 2007
Actual Study Completion Date : September 2007

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Schizophrenia

Intervention Details:
  • Drug: Quetiapine IR (Immediate Release)
    Other Name: Seroquel

Primary Outcome Measures :
  1. The primary outcome variable of this study is change from baseline in total PANSS score [ Time Frame: at Day 7 ]

Secondary Outcome Measures :
  1. Change from baseline in total PANSS scores [ Time Frame: on day 5 and 14 ]
  2. change from baseline in CGI-S and absolute CGI-I [ Time Frame: on days 5, 7 and 14 ]
  3. frequency and severity of adverse events; change in vital signs. [ Time Frame: assessed at each visit ]
  4. change from baseline in subscale PANSS and PANSS-EC scores [ Time Frame: on days 5, 7 and 14 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Men and women, aged 18 to 65 years, who require treatment for an acute episode of schizophrenia/schizoaffective disorder as judged by their doctor

Exclusion Criteria:

  • Significant and unstable conditions of hear, circulation, blood, liver, kidney; malignancies (cancer); diabetes (mellitus); history of fits or fainting. Resistance to antipsychotic medication. Current alcohol/drug abuse. Pregnant/breast feeding women.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00457899

United Kingdom
Research Site
Brentwood, Essex, United Kingdom
Research Site
Harrow, Middlesex, United Kingdom
Research Site
Surbiton, Surrey, United Kingdom
Research Site
Birmingham, United Kingdom
Research Site
Bognor Regis, United Kingdom
Research Site
Bury St Edmunds, United Kingdom
Research Site
Coventry, United Kingdom
Research Site
Crewe, United Kingdom
Research Site
Darlington, United Kingdom
Research Site
London, United Kingdom
Research Site
Sandbach, United Kingdom
Research Site
Warrington, United Kingdom
Sponsors and Collaborators
Study Director: AstraZeneca UK Medical Director, MD AstraZeneca UK
Principal Investigator: Professor Gary Sullivan, MD St Tydfil's Hospital

Additional Information: Identifier: NCT00457899     History of Changes
Other Study ID Numbers: D1443L00003
First Posted: April 9, 2007    Key Record Dates
Last Update Posted: November 27, 2007
Last Verified: November 2007

Keywords provided by AstraZeneca:
schizoaffective disorder

Additional relevant MeSH terms:
Psychotic Disorders
Mental Disorders
Pathologic Processes
Schizophrenia Spectrum and Other Psychotic Disorders
Quetiapine Fumarate
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Psychotropic Drugs